$7.43
+0.25 (+3.48%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VSTM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
27 interventional · 3 with posted results
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., Qube Research & Technologies Ltd, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, +4 more) · FINRA short interest 9.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 295 | Dec 2028 | ≤ 865 d | 2026-04-22 |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781Progression Free Survival (PFS) per blinded independent central review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole | Low Grade Serous Ovarian Cancer | 270 | 2028-10-15 | in 788 d | 2026-08-14 |
| Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)NCT07747506Duration of Treatment Exposure to Avutometinib in Combination With DefactinibOpen-label · Treatment | Phase 2 | Not yet recruiting | Drug: avutometinib + defactininb combination | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 2 | 2027-08-01 | in 347 d | 2026-08-05 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerNCT07644559Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1Randomized · Single-masked · Treatment | Phase 2 | Recruiting | Drug: VS-7375, cetuximab | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | 180 | Jun 2027 | ≤ 315 d | 2026-08-17 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerNCT07659782Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1Randomized · Single-masked · Treatment | Phase 2 | Recruiting | Drug: VS-7375 | Non-Small Cell Lung Cancer | 105 | Jun 2027 | ≤ 315 d | 2026-08-11 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerNCT07659795Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC onlyRandomized · Single-masked · Treatment | Phase 2 | Recruiting | Drug: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6 | Colorectal Cancer | 150 | Jun 2027 | ≤ 315 d | 2026-08-11 |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerNCT05669482Part A: To determine RP2D for avutometinib (VS-6766) and defactinib in combination gemcitabine and nab-paclitaxelNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas | 40 | 2026-08-31 | in 12 d | 2025-09-02 |
| Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsNCT05074810Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinibNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: avutometinib and sotorasib, avutometinib and sotorasib and defactinib | Non Small Cell Lung Cancer, KRAS Activating Mutation | 153 | Jun 2026 | — | 2026-01-12 |
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsNCT06682572Confirmed overall response rate (ORR; partial response [PR] + complete response [CR]Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Avutometinib (VS-6766) + Defactinib (VS-6063) | Low Grade Serous Ovarian Cancer, Ovarian Cancer | 16 | Dec 2025 | — | 2025-12-17 |
| A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationNCT04625270Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinibRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: avutometinib (VS-6766), avutometinib (VS-6766) and defactinib | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 225 | 2024-11-15actual | — | 2025-01-29 |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsNCT05375994Part A: To determine RP2D for avutometinib(VS-6766) in combination with adagrasibNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: avutometinib (VS-6766) and adagrasib | Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease | 12 | 2026-06-15actual | — | 2026-07-02 |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerNCT04620330To determine the optimal regimen, either avutometinib (VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, in KRAS-G12V NSCLCRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib | Non Small Cell Lung Cancer, KRAS Activating Mutation | 90 | 2023-08-29actual | — | 2024-01-12 |
| Food Effect of VS-6766 in Healthy Adult SubjectsNCT05187169Plasma Pharmacokinetics (PK) of a single dose of VS-6766 after a standardized high-fat/high-calorie meal and after fasting: AUC0-tRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: VS-6766 | Food Effect | 18 | 2022-04-12actual | — | 2022-05-10 |
| Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsNCT02004028results2024-02-20Percentage of pFAK Inhibition in Tumor TissueOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Company decided to discontinue trial to focus on development program next steps | Drug: VS-6063 | Malignant Pleural Mesothelioma | 35 | 2019-06-19actual | — | 2024-02-20 |
| Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerNCT02943317Number of Participants taking defactinib in combination with avelumab with Adverse Events as a Measure of Safety and TolerabilityNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated upon completion of escalation phase, prior to opening expansion cohorts | Drug: Part A - VS-6063, Part A - Avelumab | Epithelial Ovarian Cancer | 98 | 2018-08-28actual | — | 2019-04-30 |
| Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic MalignanciesNCT01849744Assess the safety and tolerability of VS-4718 in subjects with metastatic non-hematologic malignanciesOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision to deprioritize the program. | Drug: VS-4718 | Non Hematologic Cancers, Metastatic Cancer | 48 | Apr 2017actual | — | 2017-07-28 |
| Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer SubjectsNCT02651727Incidence of dose-limiting toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: the company's decision to de-prioritize 4718 development | Drug: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine | Pancreatic Cancer | 13 | Jan 2017actual | — | 2017-07-27 |
| Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or LymphomaNCT01991938Assess the safety and tolerability of VS-5584 in subjects with advanced non-hematologic malignancies or lymphomaOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Lack of recruitment and the company's decision to de-prioritize 5584 development | Drug: VS-5584 | Non Hematologic Cancers, Metastatic Cancer, Lymphoma | 75 | Dec 2016actual | — | 2017-01-27 |
| Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaNCT02215629To find the maximum tolerated dose of VS-4718Non-randomized · Open-label · Treatment | Phase 1 | Withdrawn | Drug: VS-4718 | Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 0 | Sep 2016 | — | 2017-01-27 |
| Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung CancerNCT01951690Demonstrate that VS-6063 (defactinib), will improve PFS at 12 weeks (PFS12) within each cohort.Open-label · Treatment | Phase 2 | Completed | Drug: defactinib (VS-6063) | Non Small Cell Lung Cancer, Lung Cancer | 55 | Jun 2016actual | — | 2017-04-13 |
| Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaNCT01870609Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placeboRandomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Interim analysis-DSMB stated good safety profile but lack of efficacy | Drug: defactinib (VS-6063), Placebo | Malignant Pleural Mesothelioma | 344 | Jan 2016actual | — | 2017-01-30 |
| A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant MesotheliomaNCT02372227Incidence of dose-limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminated | Drug: VS-5584 and VS-6063 | Relapsed Malignant Mesothelioma | 21 | Oct 2015actual | — | 2017-01-30 |
| A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsNCT02913716Urine amount excreted (Ae)Open-label · Other | Phase 1 | Completed | Drug: defactinib | Healthy Subjects | 5 | Sep 2015actual | — | 2017-01-30 |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian CancerNCT01778803Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.03 (Common Toxicity Criteria for Adverse Effects)during the study (safety and tolerability).Open-label · Treatment | Phase 1 | Completed | Drug: defactinib, Paclitaxel | Ovarian Cancer | 22 | 2015-02-23actual | — | 2017-05-17 |
| Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic MalignanciesNCT01943292results2015-11-20Assess the Safety and Tolerability of Defactinib (VS-6063) in Japanese Subjects With Non-hematologic MalignanciesOpen-label · Treatment | Phase 1 | Completed | Drug: Defactinib | Non Hematologic Cancers | 9 | 2014-06-09actual | — | 2017-03-09 |
| A Study Of PF-04554878 In Patients With Advanced Non-Hematologic MalignanciesNCT00787033Recommended Phase 2 DoseOpen-label · Treatment | Phase 1 | Completed | Drug: PF-04554878 | Cancer | 46 | Mar 2011actual | — | 2017-01-25 |
| Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic NeoplasmsNCT00666926results2012-06-14Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PF00562271, PF00562271, PF00562271, PF00562271 | Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm | 99 | Apr 2009actual | — | 2013-03-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19